Ustekinumab, a monoclonal antibody that blocks interleukin-12 and interleukin-23, is a biological therapy used to treat moderate-to-severe psoriasis. Bullous pemphigoid (BP) induced by anti–tumor necrosis factor-alfa (TNF-α) agents has been described in the literature.1-3 No cases have been reported with ustekinumab. We report a case of BP occurring in a patient treated for 9 months with ustekinumab for severe psoriasis.
No takes yet. Share an insight, caveat, or question.
Guern et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: